舒泰神（300204）8月14日主力资金净流入6101.25万元

Core Insights - Shuyatian (300204) reported a closing price of 50.98 yuan on August 14, 2025, with a 2.35% increase and a turnover rate of 3.84% [1] - The company experienced a total revenue of 63.21 million yuan in Q1 2025, a year-on-year decrease of 33.45%, while net profit attributed to shareholders was 2.34 million yuan, a year-on-year increase of 38.05% [1] Financial Performance - Total revenue for Q1 2025: 63.21 million yuan, down 33.45% year-on-year [1] - Net profit for Q1 2025: 2.34 million yuan, up 38.05% year-on-year [1] - Non-recurring net profit: 3.38 million yuan, up 23.93% year-on-year [1] - Current ratio: 1.590, quick ratio: 1.403, debt-to-asset ratio: 18.89% [1] Market Activity - Main capital inflow: 61.01 million yuan, accounting for 6.76% of transaction volume [1] - Large single net inflow: 5.59 million yuan, accounting for 6.2% of transaction volume [1] - Small single net outflow: 2.90 million yuan, accounting for 3.21% of transaction volume [1] Company Background - Shuyatian (Beijing) Biopharmaceutical Co., Ltd. was established in 2002 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 4.78 billion yuan and has made investments in 16 enterprises [2] - The company holds 249 trademark registrations and 118 patent registrations, along with 304 administrative licenses [2]